We performed this study to determine the effect on ocular blood flow and the electroretinogram of either nitric oxide synthase (NOS) inhibition, adenosine receptor blockade or the combination of both after I hr of ocular ischemia. Thirty-seven cats under general anesthesia were subjected to I hr of complete ischemia in one eye by raising the intraocular pressure above systolic blood pressure. The other eye in each animal served as a non-ischemic control. Arterial blood gas tension, systemic arterial pressure, body temperature, hematocrit, and anesthetic level were controlled in each experiment. Cats were divided into four groups. Group 1 received normal saline injections [intravenous (i.v.) and intravitreal], Group 2 adenosine receptor blockade (0.1 ml of 0.01 M 8-sulfophenyltheophylline intravitreal) and saline i.v., Group 3 NOS inhibition (30 mg/kg l-NG-nitroarginine-methyi-ester i.v.) and saline intravitreal, and Group 4 intravitreai adenosine receptor blockade and NOS inhibition i.v. A subset of Group 3 received l-arginine to investigate the reversibility of NOS inhibition, after the blood flow measurements were completed. Five minutes after the end of ischemia, blood flows in retina and choroid were measured using injections of radioactively labeled microspheres. Electroretinographic (ERG) studies were carried out before treatment, before ischemia, during ischemia, and 1, 2, 3, and 4 hr after ischemia ended. NOS inhibition significantly reduced basal blood flow in the choroid, and in the retina when combined with adenosine receptor blockade. Adenosine receptor blockade completely attenuated postischemic hyperemia in the retina, but retinal hyperemia reappeared when adenosine receptor blockade and NOS inhibition were combined. Adenosine receptor blockade had no effect on ERG recovery after ischemia. NOS inhibition led to a reduction of ERG a-and b-wave amplitudes in control eyes, that could be reversed by l-arginine. Nitric oxide (NO) appears to be a significant factor in the regulation of basal blood flow in the choroid. Adenosine appears to be a major mediator of retinal hyperemia after 60 min of ischemia. Since NOS inhibition appeared to have direct effects on ERG wave amplitudes, short-term ERG studies may be of limited use in assessing the role of NO in postischemic recovery of the retina. Our observations correlate well with the emerging role of NO as a neurotrausmitter in the retina. © 1997 Elsevier Science Ltd
INTRODUCTION
Pathological conditions such as diabetic retinopathy or central retinal artery occlusion impair blood flow in the retina. Ocular blood flow is difficult to study in humans during these conditions, yet relatively few studies have been performed to investigate ocular blood flow in *To whom all correspondence should be addressed [E-mail: rot8 @ midway.uchicago.edu]. t'Departments of Anesthesia and Critical Care, and Health Studies, University of Chicago, 5841 South Maryland Avenue, Box MC-4028, Chicago, IL 60637, U.S.A.
experimental models comparable to these clinical situations. We previously showed that ocular ischemia is followed by a significant increase (hyperemia) in retinal and choroidal blood flow (Roth & Pie~rzyk, 1994) . However, little is known about the factors that mediate this increase in ocular blood flow after ischemia. Adenosine and nitric oxide (NO) are important vasoregulators found within the retina (Blazynski & Perez, 1991; Goldstein et al., 1996; Yarnamoto et al., 1993) . In previous studies we showed that inhibition of nitric oxide synthase (NOS) by intravenous (i.v.) 1-NAME (1-N°-nitro-arginine-methyl-ester) or intravitreal 3453 3454 P. OSTWALD et al. injection of an adenosine receptor antagonist (8-sulfophenyltheophylline) partially diminished the degree of post-ischemic hyperemia in the retinal circulation after ocular ischemia in cats (Ostwald et al., 1995; Roth, 1995) . It also appeared that inhibition of NOS altered the ERG independent of the effect of ischemia (Ostwald et al., 1995) ; however, we did not assess the possible reversibility of this effect by administration of substrate (1-arginine).
The effects of adenosine receptor blockade on postischemic retinal recovery are unknown; in a preliminary study, we found that an adenosine A1 receptor agonist improved ERG b-wave recovery after ocular ischemia in rabbits (Rosenbanm et al., 1992) . In other preliminary studies, we have found significant increases in adenosine concentration during ischemia as well as in the early period of reperfusion following retinal ischemia (Roth et al., 1996a,b) . These findings suggest that adenosine is of major importance in the retina's response to ischemia. Since both NO and adenosine are involved in postischemic hyperemia, blockade of adenosine receptors and NOS inhibition should decrease post-ischemic hyperemia to a greater degree than with either maneuver alone. Simultaneous measurement of blood flow and the ERG could then provide insight into the role of post-ischemic hyperemia in retinal reperfusion injury.
A complicating factor in these studies is the effect on the circulation of the microspheres used to measure blood flow. Microspheres are a generally accepted and well described method to determine tissue blood flow, and their use allows simultaneous measurement of absolute values of retinal and choroidal blood flow, which is not possible with any other blood flow method at present (Alm et al., 1976; Buckberg et al., 1971; Heymann et al., 1977) . A disadvantage is the occurrence of artifactual changes in blood flow due to multiple microsphere injections (Roth & Pietrzyk, 1994) . In this study, we avoided this problem by using only a single microsphere injection in each animal.
METHODS

Surgical preparation
Procedures were approved by our Animal Care Committee and conformed to the ARVO Statement for Use of Animals in Ophthalmic and Vision Research. Adult cats were anesthetized with halothane and chloralose (80 mg/kg i.v.) and paralyzed with pancuronium (0.2 mg/kg/hr i.v.). After tracheal intubation, the lungs were mechanically ventilated (Anesthesia Pediatric Ventilator, Air-Shields, Hatboro, PA); PaCO2 was maintained at 28-32 mmHg (normocarbia for cats) and PaO2 at 100-150 mmHg. Arterial blood gas tensions were determined using an ABL2 blood gas analyzer (Radiometer, Copenhagen). Catheters were placed through groin incisions into bilateral femoral arteries (one catheter was advanced into the abdominal aorta for withdrawal of the reference blood sample) and into bilateral femoral veins. A left atrial catheter for microsphere injection was placed through a left thoracotomy. The anterior chamber of each eye was cannulated with a 21-g needle and connected via a three-way stopcock to a pressure transducer [to measure intraocular pressure (IOP)] and to a saline reservoir (to increase IOP). Arterial blood pressure (mean arterial pressure = MAP), left atrial pressure, and IOP were continuously monitored (P23 transducers, Spectramed, Oxnard, CA) and recorded (2800S recorder, Gould, Cleveland, OH). Esophageal temperature and hematocrit (Hct) were measured and maintained constant, using a heating pad and infusion of previously removed autologous blood, respectively. During the study, esophageal temperature was 36.5-37°C. After surgical preparation was completed, halothane concentration (measured with an Anesthetic Agent Analyzer, Puritan-Bennett, Datex Corp, Finland) was decreased to 0.2% expired.
lschemia methodology and blood flow measurement
Ocular ischemia was induced for 1 hr by elevation of IOP to 40 mmHg above systolic blood pressure in one eye of each animal (ischemic eye), as previously described (Ostwald et al., 1995) . The other eye (control eye) was maintained at normal IOP.
Retinal and choroidal blood flows in both eyes were measured by injecting 3 million 15/zm radioactively labeled microspheres (Nb 95 or Cel41, Dupont New England Nuclear, Wilmington, DE) into the left atrium 5 rain after normal IOP was restored. A reference blood sample was withdrawn from the abdominal aorta using a syringe pump (Model 22, Harvard Apparatus, Dover, MA) at 1.36 __+ 0.01 ml/min for 2 min starting 15 sec before microsphere injection. We have described this technique in detail previously (Ostwald et al., 1995; Roth, 1992a Roth, ,b, 1995 Roth & Pietrzyk, 1994) . In an earlier study, blood flows measured in paired, identically treated eyes of the same animals were not significantly different (Roth, 1995) . After completion of the experiments, radioactivity was counted in the different samples using a gamma counter (Minaxi Autogamma 5000 series, Packard, Downers Grove, IL). Blood flows (ml/100 g/ min) were calculated as previously described (Ostwald et al., 1995) .
Electroretinography
Electroretinographic (ERG) measurements were performed after at least 40 min of dark adaptation and following pupil dilation with 0.5% tropicamide (Alcon, Humacao, Puerto Rico) and cyclomydril (0.2% cyclopentolate HCI and 1% phenylephrine HCI, Alcon, Fort Worth, TX). Full-field ERG responses to single white fashes lasting 10 #sec were recorded (Neuropack 8. Nihon Kohden, Irvine, CA). The photostimulator (Grass PS33C, Quincy, MA) was held at a distance of 20 cm from both eyes. Responses were detected with corneal contact lens electrodes (ERG-jet, Nicolet Biomedical, Madison, WI) with a scalp electrode as reference. Amplified signals (200 msec analysis time, 1-1500 Hzl were stored on computer disk, printed, and analyzed.
Recordings were performed at the following time points: before drug treatment (baseline), before ischemia, at 5 min of ischemia, at 55 rain of ischemia and at 1, 2, 3, and 4 hr after ischemia ended. In control eyes, the ERG was recorded at the corresponding time points. ERG awave amplitude was measured from the baseline to the trough of the a-wave. ERG b-wave amplitude was measured from the trough of the a-wave to the peak of the b-wave. All amplitudes were normalized to baseline values and expressed as a percent of baseline.
Protocols
Cats were divided into four groups, and in each group the two eyes of each animal were treated identically as to drug or vehicle administration: Group 1 (n= 16) received 10 ml of normal saline (NS) solution i.v. and 0.1 ml of NS solution (adjusted to physiological pH) intravitreal. Group 2 (n = 7) received 10ml of NS solution i.v. and 0.1 ml 0.01 M 8-sulfophenyltheophylline in NS (SPT, Research Biochemicals Inc., Natick, MA, adjusted to physiological pH) intravitreal. Group 3 (n = 9) received 30 mg/kg 1-NC-nitro-arginine-methylester i.v. (1-NAME, Sigma Chemicals, St. Louis, MO) dissolved in 10ml NS and 0.1 ml of NS solution (adjusted to physiological pH) intravitreal. Group 4 (n = 5) received 30 mg/kg 1-NAME (in 10 ml NS) i.v. and 0.1 ml 0.01 M SPT in NS (adjusted to physiological pH) intravitreal. A subset of Group 3 (Group 3 I-ARG, n----4) received 200 mg/kg/hr 1-arginine i.v. (1-ARG, Sigma Chemicals, St. Louis, MO) after blood flow measurements were completed. 1-ARG was dissolved in NS solution and infused at a rate of 5 ml/hr, starting 15 min after the end of ischemia (following blood flow measurement), until the end of the experinaent. After completion of all experiments, the anesthetized cats were killed by injection of KC1 into the left atrium.
Drug dosing
Both drugs or NS were given 60 min before induction of ischemia. NS or 1-NAME was infused i.v. over 30 min using a syringe pump (Model 22, Harvard Apparatus, Dover, MA). The intravitreal injections were administered into the mid-vitreous using a 0.5'% 27-g needle. In a previous study, injection of the same volumes of drug or diluent into the vitreous resulted in transient increases in IOP (Roth, 1995) . To prevent these increases, and therefore avoid a possible "ischemic pre-conditioning" effect, we regulated lOP using the saline reservoir and three-way stopcock as described above. IOP was kept at 10-15mmHg during and after injections into the vitreous.
Dosing of i.v. or intravitreal agents was based upon results of previous experiments (Ostwald et al., 1995; Roth, 1995) . SPT has been shown to have antagonistic effects on adenosine A1 and A2 receptors, although it is relatively A1 selective in rat brain (Bruns et al., 1980) .
Two hours elapsed between its intravitreal administration and blood flow measurements in order to allow sufficient diffusion of the drug through the vitreous.
Statistical analysis
All data are expressed as mean_SEM. Variables within a group (i.e. control vs ischemic eyes) were compared using a paired t-test. Hemodynamic variables in Groups 2, 3, and 4 were compared to Gro~ap 1 using an unpaired t-test. Systat v 5.2 (SYSTAT, Inc., Evanston, IL) was used for analysis with P < 0.05 considered statistically significant.
To compare blood flow results between Groups 1, 2, 3, and 4, we used analysis of variance (ANOVA, Stata, Stata Corp., TX). The F-test was used to drop factors that were not statistically significant from an initial model containing 1-NAME, SPT, and their interaction as variables (Fleiss, 1986; Snedecor & Cochran, 1980) . The findings from ANOVA were further explored using t-testing, and P<0.05 was considered statistically significant. For each animal, the change in blood flow between control and ischemic eyes was calculated. We then used ANOVA to compare mean va][ues between groups for change in blood flow.
Normalized ERG a-and b-wave amplitudes in Groups 2, 3, 4, and 3 1-ARG were compared to Group 1 using an unpaired t-test with P < 0.05 considered statistically significant (Systat v 5.2, SYSTAT, Inc., Evanston, IL). 
,,°"i..., i m FIGURE 1. Blood flow (mill00 g/min) in the retina (A), and choroid (B) in the eyes of cats 5 min after the end, of ocular ischemia for 60 rain. Data are displayed as mean ± SEM, and n indicates the number of cats in each group• One eye of each animal was ischemic; the other served as a non-ischemic control. Group l received normal saline solution i.v. and normal saline solution intravitreal. Group 2 received normal saline solution i.v. and 8-sulfophenyltheophylline (SPT) intravitreal. Group 3 received 1-NG-nitro-arginine-methyl-ester (1-NAME) i.v. and normal saline solution intravitreal. Group 4 received I-NAME i.v. and SPT intravitreal. Statistical significance: *P < 0.05 for ischemic eyes compared to control eyes within the s~ane group; *P < 0.01 for ischemic eyes compared to control eyes within the same group; **P < 0.001 for ischemic eyes cc)mpared to control eyes within the same group. #Significant effect of 1-NAME on blood flow in control eyes (CoBF: 1'< 0.009). §Significant effect of I-NAME and SPT in combination on blood flow in control eyes (RetBF: P < 0.03; CoBF: F' < 0.005).
RESULTS
Bloodflows
Physiological parameters (MAP, arterial blood gas tensions, Hct, and body temperature) at the time of blood flow measurement are shown in Table 1 . The only significant difference was that Group 4 had a lower pH than Group 1.
Retinal blood flow values (RetBF) and statistically significant differences are shown in Fig. I(A) . Differences in blood flow values between control and ischemic eyes were significant in Groups 1, 3, and 4. There was a significant effect of the combination of SPT and 1-NAME in Group 4 compared to Group 1 in control eyes. Furthermore, control RetBF in Group 4 was significantly less compared to that in Groups 2 and 3 (P < 0.02 and 0.04, respectively), indicating a synergistic effect of the combination of SPT and 1-NAME. Mean change 
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(difference between control and ischemic eyes) in blood flow in Groups 1, 2, 3, and 4 was 16.7 ± 6.0, -15.3 _ 7.3, 25.6 +_ 7.0, and 17.3 ± 6.2 ml/100 g/min, respectively. Compared to Group 1, this change was significantly different in Group 2 (P < 0.004). Choroidal blood flow values (CoBF) and statistically significant differences are shown in Fig. I(B) . Differences in blood flow values between control and ischemic eyes were significant in all groups. There was a significant effect of 1-NAME on control CoBF in Group 3 and of the combination of SPT and 1-NAME in Group 4, compared to Group 1 in control eyes. Difference in control CoBF between Groups 2 and 4 was significant (P < 0.03), but not between Groups 3 and 4, indicating that the decreased control CoBF in Group 4 was due only to 1-NAME. Mean change in blood flow in Groups 1, 2, 3, and 4 was 716 ± 246, 1098 ± 373, 1251 +_ 146, and 598 _+ 150ml/100g/min, respectively (not significant between groups).
Electroretinography
Two animals from Group 1 and one from Group 2 were excluded from the ERG data analysis because intravitreal hemorrhage developed after the end of ischemia. In those experiments hemorrhage was suspected frora a decrease in ERG wave amplitudes during the experiment and verified when eyes were dissected after the experiment for blood flow analysis. ERG a-and b-waw~ amplitudes expressed as a percent of baseline appear in Figs 2 and 3, respectively. Statistical differences between a-and bwave amplitudes in the control and ischemic eyes of Groups 2, 3, 4, and 3 1-ARG compared to the respective eyes in Group 1 [Figs 2(A) and 3(A)I are indicated in Figs 2(B-E) and 3(B-E). At nearly all time points, a-and bwave amplitudes were significantly decreased in control eyes of Groups 3 and 4 compared to co~Ltrol eyes in Group 1, effects completely reversed by I-ARG [Figs 2(E) and 3(E)]. At 2 and 4 hr after ischemia ended, awave amplitude was significantly decreased in Group 3 ischemic eyes compared to ischemic eyes in Group 1, and FIGURE 2. Electroretinogram (ERG) a-wave amplitudes expressed as a percent of baseline. Data are displayed as mean+_ SEM, and n indicates the number of cats in each group. ERG was recorded at baseline, before ischemia, at 5 min of ischemia, at 55 rain of ischemia and 1, 2, 3, and 4 hr after the end of ischemia. One eye: of each animal was ischemic; the other served as a non-ischemic control. (A) Group 1 received normal saline solution i.v. and normal saline solution intravitreal. (B) Group 2 received normal saline solution i.v. and 8-sulfophenyltheophylline (SPT) intravitreal. (C) Group 3 received l-N~-nitro-arginine-methyl-ester (I-NAME) i.v. and normal saline solution intravitreal. (D) Group 4 received 1-NAME i.v. and SPT intravitreal. (E) Group 3 1-ARG received 1-NAME i.v., normal saline solution intravitreal, and 1-arginine i.v. Statistical significance: *P < 0.05 for control eyes compared to control eyes in Group 1; *P< 0.01 for control eyes compared to control eyes in Group 1; **P < 0.001 for control eyes compared to control eyes in Group 1. #P < 0.05 for ischemic eyes compared to ischemic eyes in Group 1; §P < 0.001 for ischemic eyes compared to ischemic eyes in Group 1.
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. for the b-wave, at 2 and 3 hr after ischemia ended in Group 4 compared to Group 1.
DISCUSSION
In this study, NOS inhibition reduced basal blood flow in the choroid, and when combined with adenosine receptor blockade, in the retina as well. Adenosine receptor blockade completely attenuated post-ischemic hyperemia in the retina, but retinal hyperemia reappeared when adenosine receptor blockade was combined with NOS inhibition. Hyperemia was unaltered by NOS inhibition. Adenosine receptor blockade did not alter ERG in ischemic or control eyes. NOS inhibition or the combination with adenosine receptor blockade significantly reduced a-and b-wave amplitudes in control eyes. 1-ARG completely reversed the effects of NOS inhibition on a-and b-wave amplitudes in control eyes.
Our present findings suggest that adenosine is not involved in the regulation of basal vascular tone in the retina and confirm earlier observations by us and by others that adenosine is involved in the retinal vascular response to hypoxia or ischemia (Gidday & Park, 1993; Roth, 1995) . However, in the present study the effect of SPT on postischemic retinal hyperemia was even more dramatic than in our previous study (Roth, 1995) , where SPT resulted in partial attenuation of hyperemia. This difference is likely due to several differences in study design. Firstly, we allowed significan~;ly more time (>2 hr) for diffusion of SPT in the vitreous. Secondly, a single microsphere injection was used to prevent artifactual changes in blood flow (Roth & Pietrzyk, 1994) , and thirdly, IOP was controlled 6uring and after intravitreal injections to prevent a possible "pre-conditioning" effect from transient elevations in lOP.
Adenosine and its receptors have been found in the retina of different species (Blazynski et al., 1989a,b; Braas et al., 1987) , and adenosine agonists decreased the release of excitatory amino acids from the ischemic brain (Simpson et al., 1992) . In addition, neuroprotective effects of adenosine agonists have been shown by several investigators; for review see Rudolphi et al. (1992) . In preliminary studies, we showed that an adenosine AI receptor agonist improved recovery of the ERG b-wave after ischemia in rabbits (Rosenbaum er al., 1992) , and that adenosine concentration in the retina increased not only during ischemia, but remained elewtted until 30 rain of reperfusion after 60 min retinal ischemia in rats (Roth et al., 1996a,b) .
Despite evidence suggesting an :involvement of adenosine in the vascular response to retinal ischemia, we could not detect any deleterious effects of adenosine blockade on the recovery of the ERG b-wave. The lack of effect of SPT on the ERG in our study could be due to incomplete receptor blockade. Yet we found complete attenuation of postischemic retinal hyperemia, implying that adenosine receptors were likely antagonized. Our findings therefore may indicate that attenuation of hyperemia does not alter outcome. However, this potentially important inference must be viewed cautiously, as our follow-up period was only until 4 hr after ischemia concluded, and furthermore, the ERG may be insufficiently sensitive as an outcome measurement. Effects of hyperemia, such as retinal edema or other forms of delayed reperfusion injury, may not become evident until much later in the post-ischemic time course. Future studies to assess the impact of hyperemia on retinal injury should be performed using more sensitive measurements during a longer post-ischemic follow-up time.
The role of NO in retinal physiology has been reviewed by us recently elsewhere (Goldstein et al., 1996) . In a previous study in cats, NOS inhibition did not result in a significant reduction of basal blood flow in the retina, and a trend for decrease in basal choroidal flow did not reach statistical significance (Ostwald et al., 1995) . In the present study we found that NOS inhibition reduced basal blood flow in the choroid. This may have in part been due to a generally lower MAP in the previous study. We used a greater number of animals in the present study in combination with an improved statistical analysis. The greater sample size may explain the ability to demonstrate statistical significance in the present study. Methodological error is an unlikely probability, since retinal and cerebral blood flow (latter data not shown) were similar in the two studies. That the effect of 1-NAME was more pronounced in the choroid compared to the retina would be expected; NOS-containing nerve fibers derived predominantly from the pterygopalatine ganglion heavily innervate the choroidal blood vessels, especially in the temporal-central region, in both rat and human eyes (Fltigel et al., 1994; Yamamoto et al., 1993) .
The combination of NOS inhibition and adenosine receptor blockade produced a synergistic decrease in basal blood flow in the retina. While some have theorized that adenosine and NO may interact in the vasculature, or that one may serve as a messenger to produce the other's effects (Dirnagl et al., 1994) , this synergistic effect upon basal blood flow has not been previously demonstrated in vivo.
In our earlier study, three of nine 1-NAME-treated cats had no hyperemia. Others have also found inconsistency in the postischemic hyperemia phenomenon (Takeshima et al., 1994) , perhaps the result of severe endothelial or other damage in the vasculature, depletion of vasodilatory substances, thrombosis, or vasospasm. However, hyperemia was seen consistently in the 1-NAME group in the present study, and all three statistical comparisons showed no effect of 1-NAME on basal or postischemic RetBF. Inclusion of the non-hyperemic animals in the earlier study is the most probable reason for the findings of decreased hyperemia in the 1-NAME treated group in the previous study. It is most likely that the present findings are accurate and reliable, and reflect a minor role for NO in the postischemic RetBF response, in contrast to the sim~Imaeously demonstrated major role of adenosine.
We observed the striking phenomenon that retinal hyperemia was blocked by adenosine receptor blockade, not altered by NOS inhibition, but reappeared when adenosine receptor blockade and NOS inhibition were combined. With the assumption that adenosine is the main mediator of postischemic retinal hyperemia, we theorized that NOS inhibition may have increased retinal adenosine concentration to an extent sufficient to overcome competitive adenosine receptor blockade with SPT. That NOS inhibition could increase adenosine concentration is supported by an observation in coronary arteries. Kostic and Schrader (1992) found that 60 sec of coronary ischemia in the isolated guinea pig heart was followed by reactive hyperemia and by an increase of adenosine and NO concentrations. Inhibition of NOS by 1-NAME significantly increased adenosine release under basal and postischemic conditions. This effect was enhanced when oxyhemoglobin, a potent scavenger of NO, was given in addition to 1-NAME, while d-NAME, the stereoisomer of 1-NAME, had no effect on adenosine concentrations. A similar effect of NOS inhibition on postischemic adenosine concentrations in the retina could explain the observation that combined NOS inhibition and adenosine receptor blockade resulted in retinal hyperemia.
Little is known about the effect of NO donors or NOS inhibition on the ERG in vivo. The NO donor sodium nitroprusside (SNP) or NOS inhibitor nitro-lt-arginine (I-NA) were administered intravitreally to rabbits (Veriac et al., 1993) , but the effect of either treatment o:a the ERG bwave amplitude was not described. Maynard et al. (1995) , studying isolated rabbit retina, found an effect of NOS inhibition only on compound action potentials from the optic nerve, but not from the Pill component, supposed to represent the photoreceptor activity. We found that NOS inhibition significantly reduced the ERG a-and b-wave amplitudes in control eyes in those groups that received 1-NAME or 1-NAME and SPT. The effect of 1-NAME could be reversed by 1-ARG, indicating the specific involvement of NOS. Similar, although less dramatic, results have recently been found by us in the intact rat retina (Rosenbaum et al., 1996) . The latter findings suggest that the effect of NOS inhibition on retinal electrophysiological function may, in part, be species dependent. Our observations are the first to suggest a role of NO in visual transduction in the retina in intact vertebrate animals. Since NOS inhibition decreased choroidal but not RetBF, it is pos~dble that the ERG effects we found were partially related to decreased blood flow; therefore, our study cannot completely distinguish between possible neural-or vascularmediated mechanisms of action of NOS :inhibition on the cat retina.
The ERG a-wave is generated in photoreceptors (Tomita & Yanagida, 1981) . A decrease in a-wave amplitude due to NOS inhibition is consistent with the findings that 1-ARG and SNP altered light responses and dark voltage in isolated frog rods (Schmidt et al., 1992; Tsuyama et al., 1993) . NOS is coupled to a soluble guanylate cyclase in photoreceptors (Koch et al., 1994) and cGMP-gated cation channels in these cells are responsible for the dark current (Fesenko et al., 1985; Lagnado & Baylor, 1992) , Hence, NOS inhibition could have decreased cGMP concentrations and thereby altered the dark current. Since cGMP-independent effects of NO on Ca 2+ currents in photoreceptors have also been shown, another mechanism may be that NOS inhibition interfered with synaptic transmission (Kurenny et al., 1994) . Reversal of the effect of 1-NAME using an excess of 1-ARG may have resulted in an increased synthesis of NO. Interestingly, we found that application of 1-ARG significantly increased the ERG a-wave at the "2 hr" and "3 hr" time point in control eyes which may be due to increased NO levels.
The ERG b-wave is believed to represent light-evoked depolarizations in ON-bipolar cells (Stockton & Slaughter, 1989) , which contain an NO-sensitive soluble guanylate cyclase (Shiells & Falk, 1992a) . Similar to photoreceptors, they also contain a cGMP-gated cation channel (Shiells & Falk, 1992b) . Depolarization of ONbipolar cells in response to photoreceptor light responses is mediated by this cGMP-gated ion channel (Nawy & Jahr, 1990 , 1991 . Since ON-bipolar cells are not known to contain NOS, the NO which may act upon them is likely generated in adjacent amacrine cells (Koistinaho et al., 1993) . Hence, a possible explanation for the effects of NOS inhibition on ERG b-wave amplitudes that we observed could be that synaptic transmission within the inner retina was altered.
Effects of NOS inhibition on visual transduction and on ERG wave amplitude render it difficult to differentiate the depressant effects of NOS inhibition on visual transduction from the effect of retinal damage itself. Furthermore, NOS inhibition has been used as a treatment of septic shock in patients (Petros et al., 1991; Billiar, 1995) . The striking effects of NOS inhibition on the ERG that we observed suggest the need for caution in initiating such therapy. For future investigations on retinal outcome after ischemia using NO donors or NOS inhibition, simultaneous histologic studies may be of additional value (Hughes, 1991) . In our study, eye tissues were needed for blood flow analysis and could not be used for histologic evaluation.
In summary we found the following effects of adenosine receptor blockade and NOS inhibition on ocular blood flow and the electroretinogram:
1. NOS inhibition decreased basal CoBF, and the combination of NOS inhibition and adenosine receptor blockade produced synergistic decreases in RetBF. 2. Adenosine receptor blockade completely attenuated postischemic hyperemia in the retina. 3. The combination of adenosine receptor blockade and NOS inhibition had effects on control and postischemic RetBF that indicate interactions between adenosine and NO.
4. NOS inhibition reduced ERG a-and b-wave amplitudes in control eyes, an effect completely reversed by 1-arginine, indicating that NO is likely involved in visual transduction processes in vertebrate animals.
